Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390547 | 0.92 | PKM (0.33) | PKMHSD17B10TP53DGAT1GPR119 | |
| SCHEMBL13390634 | 0.90 | ALDH1A1 (0.35) | IRAK4PKMHSD17B10DGAT1ALDH1A1 | |
| SCHEMBL3298189 | 0.90 | KEAP1 (0.33) | ALDH1A1 | |
| SCHEMBL3295727 | 0.89 | GPR119 (0.40) | GPR119 | |
| SCHEMBL13390883 | 0.86 | IRAK4 (0.34) | IRAK4PKMHSD17B10TP53DGAT1 | |
| SCHEMBL13390635 | 0.86 | IRAK4 (0.36) | IRAK4PKMHSD17B10TP53DGAT1 | |
| SCHEMBL13390511 | 0.85 | PKM (0.33) | IRAK4PKMHSD17B10TP53DGAT1 | |
| SCHEMBL13390833 | 0.84 | PKM (0.34) | IRAK4PKMHSD17B10TP53DGAT1 | |
| SCHEMBL13390182 | 0.84 | IRAK4 (0.33) | IRAK4PKMHSD17B10TP53DGAT1 | |
| SCHEMBL13390357 | 0.84 | DGAT1 (0.34) | IRAK4PKMHSD17B10TP53DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | IRAK4 2516/4885PKM 117/4885HSD17B10 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.